AtriCure, Inc.’s Post

View organization page for AtriCure, Inc., graphic

37,190 followers

Reduced antiarrhythmic drug use, superior freedom from Atrial Arrhythmia recurrence* and fewer repeat ablations are just a few of the positive outcomes we’re seeing two years out with the randomized-controlled CEASE-AF Trial using Hybrid ablation and LAAE compared to endocardial ablation alone. To learn more about the CEASE-AF Trial, visit https://okt.to/mbQeau *Freedom from atrial arrhythmias were defined as atrial fibrillation, atrial flutter, atrial tachycardia in patients off anti-arrhythmic drugs (AADs) except previously failed AADs at doses not exceeding those previously failed. Patients had an enlarged left atrium >4 cm ≤ 6 cm. Hybrid data were directly compared to endocardial ablation alone.

To view or add a comment, sign in

Explore topics